- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01839552
An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients. (FCNS)
An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids.
Lazanda is a prescription nasal spray medicine that contains the medicine fentanyl. It is used to manage breakthrough pain in adults with cancer who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Lazanda is started only after taking other opioid pain medicines and the patient's body has become used to them (opioid tolerant).
The purpose of this study is to assess the ability of Lazanda to control pain during an episode of breakthrough pain in cancer patients.
Study Overview
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- James Graham Brown Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients who meet the following criteria will be eligible:
- At least 18 years of age or older.
- Diagnosed with cancer.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Patients with cancer who are experiencing episodes of BTPc in spite of optimized background analgesia with at least 60 mg/day of morphine (or equivalent analgesic) for at least 7 days.
- Patients with cancer currently using an SAO (short acting opioid) to manage their episodes of BTPc.
- Patients with cancer who have failed to obtain a timely response, as determined by the Principal Investigator, to pain from their SAO therapy.
- Laboratory values consistent with the stage of disease that are deemed clinically insignificant by the investigator.
- Female patients of child bearing potential or male patients with partners of child bearing potential who are using an adequate form of contraception before study entry, and agree to use an adequate form of contraception for an additional month after the study. Adequate contraception is defined as the use of any hormonal contraception or intra-uterine device by the female patient/partner plus use by at least 1 of the partners of an additional spermicide-containing barrier method of contraception. The use of a barrier method alone or abstinence is not considered adequate.
- Willing and able to give written informed consent before participating in the study.
Exclusion Criteria:
Patients meeting the following criteria will be excluded from the study:
- Patients who are not opioid tolerant.
- Patients with a known intolerance or hypersensitivity to fentanyl.
- Physical abnormalities of the nose that could affect nasal absorption.
- Patients with uncontrolled or rapidly escalating pain.
- Patients with a history of alcohol or substance abuse.
- A clinically significant medical history (past or present) of any disease that would compromise the study or the well-being of the patient .
- Patients who have participated in another clinical trial with an analgesic within the last month.
- Patients who have previously used FCNS and did not have adequate responses.
- Female patients with a positive pregnancy test or who are currently lactating.
- Patients who are taking medications that are known inhibitors of the CYP3A4 isoenzyme, such as ketoconazole.
- Patients who have taken a monoamine oxidase inhibitor within 14 days before a dose of study medication.
- Patients who are unsuitable for inclusion for any other reason, in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fentanyl Citrate Nasal Spray (FCNS)
Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Intensity
Time Frame: Assessed at end of Maintenance Stage
|
The primary efficacy outcome measure is pain intensity difference at 15 minutes (PID15) after dosing during the Maintenance Stage.
(PID15 is defined as the difference between pain intensity at 15 minutes and baseline.)Maintenance
stage is defined as 6 breakthrough pain episodes for up to 6 weeks.
|
Assessed at end of Maintenance Stage
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Management Satisfaction
Time Frame: participants will be followed during maintenance phase, up to 6 weeks
|
The key secondary outcome measure is the proportion of episodes that the patient defines as satisfactorily managed at 15 minutes. Satisfaction will be considered to have been achieved for an individual episode of BTPc(Breakthrough pain)if the patient rates pain management as "Satisfied" or "Very Satisfied." Patients complete a satisfaction questionnaire at end of study. |
participants will be followed during maintenance phase, up to 6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Goetz Kloecker, MD, FACP, MBA, MSPH, James Graham Brown Cancer Center-University of Louisville
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCC-CA-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
Clinical Trials on Fentanyl Citrate Nasal Spray (FCNS)
-
Archimedes Development LtdCompleted
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
Archimedes Development LtdCompleted
-
University of ChicagoMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Withdrawn
-
Viiral Nordic ABCompleted
-
Imperial College LondonGlaxoSmithKlineCompleted
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Sara EspinozaThe University of Texas Health Science Center, Houston; The University of Texas... and other collaboratorsCompletedObesity | Sedentary Lifestyle | Sarcopenia | Aging | Sarcopenic ObesityUnited States